Baidu and OpenAI announced premium models at no cost over the next few months after DeepSeek’s generative AI caused a lot of buzz.

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

"At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie ... option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and ...

A 3D model accurately mimicking the blood-brain barrier (BBB) in a laboratory environment has been successfully developed by ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...

Cancer models developed with 3D bioprinting technology allow for rapid evaluation of individual drug responses.

A collaborative research team led by Professor Jinah Jang from the Department of Mechanical Engineering and the Department of ...